Stephens Adjusts Price Target on Charles River Laboratories International to $250 From $280
Charles River Analyst Ratings
Charles River Analyst Ratings
Charles River Analyst Ratings
Charles River Analyst Ratings
Charles River Analyst Ratings
Charles Rhyee Maintains Hold on Charles River Labs Amidst Revenue and Market Uncertainties
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)
Charles River Analyst Ratings
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300
Buy Rating on Charles River Labs Amidst Solid Q1 Performance and Positive Market Outlook
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Charles River Labs (CRL) and Neurocrine (NBIX)
Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278
Deutsche Bank Raises Price Target on Charles River Laboratories to $300 From $275, Keeps Buy Rating
Charles River Analyst Ratings
Morgan Stanley Raises Price Target on Charles River Laboratories International to $235 From $205, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Charles River Labs (CRL) and Shockwave Medical (SWAV)
Evercore ISI Remains a Buy on Charles River Labs (CRL)
Baird Adjusts Price Target on Charles River Laboratories International to $268 From $252, Maintains Outperform Rating
Charles River Analyst Ratings